OZURDEX 700 micrograms intravitreal implant in applicator clinical trials

A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared with Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects with Diabetic Macular Edema (OXEYE).

This study looks at a new treatment called OXU-001 for diabetic macular edema (DME), a common eye condition. It compares OXU-001 with an existing treatment, OZURDEX, to see which is safer and works better at improving eyesight and reducing swelling in the eye.